OraSure Technologies (OSUR) Projected to Post Quarterly Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR) is anticipated to announce its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $28.9610 million for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 5:00 PM ET.

OraSure Technologies Price Performance

OraSure Technologies stock opened at $2.74 on Monday. The firm has a 50 day simple moving average of $3.15 and a 200-day simple moving average of $3.01. OraSure Technologies has a 1-year low of $2.36 and a 1-year high of $4.60. The stock has a market cap of $200.40 million, a price-to-earnings ratio of -4.09 and a beta of 0.46.

Institutional Investors Weigh In On OraSure Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Cannell Capital LLC raised its holdings in shares of OraSure Technologies by 33.7% in the 2nd quarter. Cannell Capital LLC now owns 1,864,989 shares of the medical instruments supplier’s stock valued at $5,595,000 after purchasing an additional 470,536 shares in the last quarter. Bridgeway Capital Management LLC raised its holdings in shares of OraSure Technologies by 9.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 1,790,260 shares of the medical instruments supplier’s stock valued at $5,371,000 after purchasing an additional 154,985 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of OraSure Technologies by 9.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 324,967 shares of the medical instruments supplier’s stock valued at $975,000 after purchasing an additional 28,464 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of OraSure Technologies by 14.1% in the 2nd quarter. Jane Street Group LLC now owns 157,871 shares of the medical instruments supplier’s stock valued at $474,000 after purchasing an additional 19,494 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new stake in shares of OraSure Technologies in the 2nd quarter valued at $31,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of OraSure Technologies in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, OraSure Technologies currently has an average rating of “Reduce” and an average price target of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.